Malaria

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

Podcast: Keep up-to-date on the latest industry news

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  The industry has seen breakthroughs announced in malaria treatment, epilepsy and major… Read More

#News

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

This week in drug discovery (28 November – 2 December)

News round-up for 28 November – 2 December by DDW Digital Content Editor Diana Spencer  The last seven days have seen breakthroughs announced in malaria treatment, epilepsy and major depressive disorders. The NHS in England has fast tracked another cancer drug, and, in Covid-19 news, researchers have… Read More

#News

Child receiving treatment for malaria
#Malaria #Phase III trial #Treatment resistance

Once-daily malaria drug could overcome treatment resistance

Novartis and Medicines for Malaria Venture (MMV) will progress ganaplacide/lumefantrine-solid dispersion formulation (SDF) into Phase III development for the treatment of patients with malaria due to Plasmodium falciparum.    Ganaplacide is a novel agent with a new mechanism of action, which is combined with a new formulation of… Read More

#Editor's Choice #News

#Covid-19 #Geographic atrophy #Immunology / Virology & Vaccines #Malaria #Neuroscience #Psychedelics

Catch up on the latest DDW Highlights episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In a week that saw magic mushrooms making the… Read More

#News

#Covid-19 #Covid-19 vaccine #Drug development #Drug discovery #Gene therapy #Geographic atrophy #Malaria #Monoclonal antibodies #Psychedelics #Treatment-resistant depression

This week in drug discovery (31 October – 4 November)

News round-up for 31 October – 4 November by DDW Digital Content Editor Diana Spencer  In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. Meanwhile, the quest to understand… Read More

#News

Mosquito against yellow background
#Malaria #Monoclonal antibodies #National Institute of Allergy and Infectious Diseases #Phase II trial #Sub-Saharan Africa

Monoclonal antibody could transform malaria prevention

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa.   The antibody was up to 88.2% effective at preventing infection over a 24-week period, demonstrating for the first time that a monoclonal antibody can… Read More

#News #Trending News

#Biologics #Cell and gene therapy #Malaria #Manufacturing #Oncology

This week in drug discovery (26-30 September)

This week in drug discovery (26-30 September) News round-up by DDW Editor Reece Armstrong. An interesting week across the board for the pharma sector with the first biologic for severe asthma approved in the EU. Elsewhere researchers have discovered new ways of  identifying cancer cells and a manufacturing system could… Read More

#News

Mosquito
#Biotechnology #Investment #Malaria

Malaria specialists secure $1.5m investment round  

US biotechnology start-up LivFul has secured a $1.5m investment to expand its work saving lives from malaria and other insect-borne diseases, and to support the company’s growth plans.    The company’s major markets are now opening up following the pandemic, with interest in Livful’s Enhanced Insect Repellent ramping up. Livful is… Read More

#Business & Investment #News

#Clinical trials #Immunology / Virology & Vaccines #Malaria #US

Positive results for US Malaria vaccine, trial shows 

A monoclonal antibody (mAb) treatment for the prevention of Malaria has shown encouraging results in a US Phase I clinical trial.   The mAb, known as L9LS, was developed by scientists at the National Institutes of Health’s (NIH) Vaccine Research Centre (VRC). L9LS is a laboratory-made version of… Read More

#News

#AstraZeneca #GSK #Malaria #University of Birmingham

This week in drug discovery (25-29 April)  

News round-up by DDW’s Reece Armstrong for 25-29 April     Q1 earnings, formulations to tackle blindness, liver cancer therapies and opportunities for malaria treatments are some of the themes of this week’s news round-up.  What’s behind GSK’s strong Q1 earnings?  DDW Deputy… Read More

#News

#Malaria #Vaccines #World Malaria Day

World Malaria Day – efforts by the pharma industry  

Despite continuous work by the scientific community, malaria remains one of the largest and deadliest diseases on the planet. The disease, which is spread via the bites of female Anopheles mosquitoes, was responsible for 627,000 deaths in 2020, with 95% of those occurring in Africa.    The disease… Read More

#News

#Clinical trials #Covid-19 #Healthcare #HIV #Malaria #Public health

World Health Day: We celebrate global drug discovery

As we celebrate World Health Day, Lu Rahman looks at some of the key drug discovery and development successes over the last year that have significantly helped improved the health and wellbeing of the global population.   Malaria breakthroughs  According to The World Health Organization (WHO) more than a million people in Africa… Read More

#Editor's Choice #Exclusive Content #News

#Clinical trials #Infectious diseases #Malaria

Landmark approval of child-friendly malaria treatment 

According to the Medicines for Malaria Venture (MMV),the Australian Therapeutic Goods Administration (TGA) has approved the use of single-dose Kozenis (tafenoquine) in children aged two years and above in combination with chloroquine for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria.  The approval… Read More

#News #Trending News

#Immunology / Virology & Vaccines #Malaria

WHO recommends GSK malaria vaccine for children at risk 

The World Health Organization (WHO) has recommended GlaxoSmithKline (GSK)’s RTS,S malaria vaccine to be given to children living in sub-Saharan Africa who are at risk of contracting Malaria.  RTS,S is the first and only malaria vaccine to have been shown in pivotal long-term clinical trials to significantly reduce… Read More

#News #Trending News

#Antibodies #Immunology / Virology & Vaccines #Malaria #Monoclonal antibodies

Monoclonal antibody prevents malaria in NIH trial 

One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health (NIH) safely prevented malaria for up to nine months in people who were exposed to the malaria parasite. The clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria… Read More

#News #Trending News

#Clinical trials #Immunology / Virology & Vaccines #Malaria #Vaccines

Investigational malaria vaccine gives strong, lasting protection

Two US Phase I clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs—an approach termed chemoprophylaxis vaccination. Read More

#News